Literature DB >> 23617869

Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence.

Daniel F Gros1, Melissa E Milanak, Kathleen T Brady, Sudie E Back.   

Abstract

BACKGROUND AND OBJECTIVES: Comorbid substance use disorders and mood and anxiety disorders are associated with more severe psychiatric symptoms, social and occupational impairment, and economic burden. To date, the majority of research has focused on comorbidity in illicit drug users, rather than prescription drug users. To address this gap in the literature, the present cross-sectional study investigated the clinical profiles of individuals with prescription opioid dependence with or without comorbid mood and anxiety disorders.
METHODS: Ninety individuals with prescription opioid use were recruited to participate in the study procedures. All participants completed a structured clinical interview and series of self-report measures. RESULTS AND
CONCLUSIONS: Of the 85 individuals with prescription opioid dependence, 47.1% (n = 40) were diagnosed with a comorbid mood or anxiety disorder. The findings showed that individuals with prescription opioid dependence and comorbid mood and anxiety disorders demonstrated significantly more severe alcohol use, psychiatric symptoms, and sleep impairment than individuals without comorbidity. SCIENTIFIC SIGNIFICANCE: The findings highlight the frequency and severity of co-occurring mood and anxiety disorders in individuals with prescription opioid dependence and suggest that integrated interventions are needed to address these growing problems.
Copyright © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Year:  2013        PMID: 23617869      PMCID: PMC6206504          DOI: 10.1111/j.1521-0391.2012.12008.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  16 in total

1.  Characteristics and correlates of men and women with prescription opioid dependence.

Authors:  Sudie E Back; Katie M Lawson; Lauren M Singleton; Kathleen T Brady
Journal:  Addict Behav       Date:  2011-03-25       Impact factor: 3.913

2.  Posttraumatic Stress Disorder and Co-Occurring Substance Use Disorders: Advances in Assessment and Treatment.

Authors:  Jenna L McCauley; Therese Killeen; Daniel F Gros; Kathleen T Brady; Sudie E Back
Journal:  Clin Psychol (New York)       Date:  2012-09-01

3.  Use of an integrated therapy with prolonged exposure to treat PTSD and comorbid alcohol dependence in an Iraq veteran.

Authors:  Sudie E Back; Therese Killeen; Edna B Foa; Elizabeth J Santa Ana; Daniel F Gros; Kathleen T Brady
Journal:  Am J Psychiatry       Date:  2012-07       Impact factor: 18.112

Review 4.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

Review 5.  Pain assessment: global use of the Brief Pain Inventory.

Authors:  C S Cleeland; K M Ryan
Journal:  Ann Acad Med Singapore       Date:  1994-03       Impact factor: 2.473

6.  Understanding comorbidity between substance use, anxiety and affective disorders: broadening the research base.

Authors:  Wayne Hall; Louisa Degenhardt; Maree Teesson
Journal:  Addict Behav       Date:  2009-03-24       Impact factor: 3.913

7.  Toward an improved model of treating co-occurring PTSD and substance use disorders.

Authors:  Sudie E Back
Journal:  Am J Psychiatry       Date:  2010-01       Impact factor: 18.112

8.  Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network.

Authors:  Denise A Hien; Huiping Jiang; Aimee N C Campbell; Mei-Chen Hu; Gloria M Miele; Lisa R Cohen; Gregory S Brigham; Carrie Capstick; Agatha Kulaga; James Robinson; Lourdes Suarez-Morales; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2009-11-16       Impact factor: 18.112

9.  Alcohol use disorders comorbid with anxiety, depression and drug use disorders. Findings from the Australian National Survey of Mental Health and Well Being.

Authors:  Lucy Burns; Maree Teesson
Journal:  Drug Alcohol Depend       Date:  2002-12-01       Impact factor: 4.492

10.  Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients.

Authors:  Laxmaiah Manchikanti; James Giordano; Mark V Boswell; Bert Fellows; Rajeev Manchukonda; Vidyasagar Pampati
Journal:  J Opioid Manag       Date:  2007 Mar-Apr
View more
  15 in total

1.  Opioid use disorder research and the Council for the Advancement of Nursing Science priority areas.

Authors:  Patricia Eckardt; Donald Bailey; Holli A DeVon; Cynthia Dougherty; Pamela Ginex; Cheryl A Krause-Parello; Rita H Pickler; Therese S Richmond; Eleanor Rivera; Carol F Roye; Nancy Redeker
Journal:  Nurs Outlook       Date:  2020-04-09       Impact factor: 3.250

2.  Medication Adherence and HIV Symptom Distress in Relation to Panic Disorder Among HIV-Positive Adults Managing Opioid Dependence.

Authors:  Jesse D Kosiba; Adam Gonzalez; Conall O'Cleirigh; Steven A Safren
Journal:  Cognit Ther Res       Date:  2014-08

3.  Oxycodone decreases anxiety-like behavior in the elevated plus-maze test in male and female rats.

Authors:  Adriaan W Bruijnzeel; Azin Behnood-Rod; Wendi Malphurs; Ranjithkumar Chellian; Robert M Caudle; Marcelo Febo; Barry Setlow; John K Neubert
Journal:  Behav Pharmacol       Date:  2022-08-03       Impact factor: 2.277

4.  Stressful life events and prescription opioid use during pregnancy: findings from the 2019 pregnancy risk assessment monitoring system.

Authors:  Alexander Testa; Allison D Crawford; Dylan B Jackson; Alison Gemmill
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-08-10       Impact factor: 4.519

5.  Co-occurring prescription opioid use problems and posttraumatic stress disorder symptom severity.

Authors:  Andrea Meier; Chantal Lambert-Harris; Mark P McGovern; Haiyi Xie; Melissa An; Bethany McLeman
Journal:  Am J Drug Alcohol Abuse       Date:  2014-05-08       Impact factor: 3.829

6.  Activation of sphingosine-1-phosphate receptor subtype 1 in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in rodents.

Authors:  Timothy M Doyle; Kali Janes; Zhoumou Chen; Peter M Grace; Emanuela Esposito; Salvatore Cuzzocrea; Tally M Largent-Milnes; William L Neumann; Linda R Watkins; Sarah Spiegel; Todd W Vanderah; Daniela Salvemini
Journal:  Pain       Date:  2020-09-01       Impact factor: 7.926

7.  A retrospective analysis focusing on a group of patients with dual diagnosis treated by both mental health and substance use services.

Authors:  Rosaria Di Lorenzo; Agnese Galliani; Alessia Guicciardi; Giulia Landi; Paola Ferri
Journal:  Neuropsychiatr Dis Treat       Date:  2014-08-11       Impact factor: 2.570

8.  Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.

Authors:  Andrew S Huhn; Patrick H Finan
Journal:  Exp Clin Psychopharmacol       Date:  2021-06-10       Impact factor: 3.157

9.  Prolonged Opioid Use After Surgery for Early-Stage Breast Cancer.

Authors:  Chan Shen; J Douglas Thornton; Dian Gu; Daleela Dodge; Shouhao Zhou; Weiguo He; Hui Zhao; Sharon H Giordano
Journal:  Oncologist       Date:  2020-06-02       Impact factor: 5.837

10.  Depression and Anxiety Among Patients on Chronic Opioid Therapy.

Authors:  Muhamad Y Elrashidi; Lindsey M Philpot; Priya Ramar; William B Leasure; Jon O Ebbert
Journal:  Health Serv Res Manag Epidemiol       Date:  2018-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.